StreetAlpha.app
Home › Stocks › SLS

SELLAS Life Sciences Group, Inc. (SLS)

Healthcare
$19.18
▲ +156.76%
LAST CLOSE · NOV 17

SELLAS develops cancer immunotherapy and targeted drug candidates for blood cancers and solid tumors. It last closed at $19.18 on Nov 17, up 156.76% on the day. Over the past 90 days StreetAlpha recorded 5 whale options trades in SLS, 40% of them bullish and 60% bearish. In the past 30 days there were 2 dark pool prints totaling $795K, the largest $457K.

AI Auto Pilots
Is SLS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$35.8M
EPS (diluted)
−$0.20
Valuation
Market cap
$3.9B
203.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$134.7M
At Sep 30
Shareholder equity
$131.8M
Shares outstanding
203.9M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $7.6M$7.6MFY2021FY2022: $1.0M$1.0MFY2022FY2023: $0$0FY2023

From SLS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

SLS · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 48% above its 20 day and 43% above its 50 day average. It is 54% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 77), overbought. The nearest support is the Pivot S1 at $15.64, and the nearest resistance the Pivot at $20.26.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 11.2%/day
Key levels
$24.8952 week high+29.8%
$23.81Pivot R1+24.1%
$20.26Pivot+5.6%
$19.18Last close
$15.64Pivot S1−18.5%
$12.64Swing low (Sep 1)−34.1%
$11.92100 day average−37.9%
$11.0150 day average−42.6%
$9.9820 day average−48.0%
$8.88200 day average−53.7%
$1.3952 week low−92.8%
Indicators
RSI (14)76.63Overbought above 70Overbought
MACD-0.07Above its signal lineBullish
Stochastic29.2Middle of its rangeNeutral
ADX (14)28.6Trending up
Williams %R-32.2Oversold below −80, overbought above −20Neutral
CCI (20)353.1Oversold below −100, overbought above 100Overbought
Rate of change+116.2%Change over 10 sessionsBullish
ATR (14)$2.15Typical daily range, 11.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SLS

What happened before

See how SLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish2 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow SLS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
5
Bullish
2
40%
Bearish
3
60%
Date span
Aug 21 – Oct 29
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$795K
Largest print
$457K
Loading…

SLS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲140 buying vs 62 selling
  • ▼Held by funds -1.0 pts
  • ▲Funds holding +24
  • ▼Superinvestors: 0 added, 1 cut
  • ▲Put/call 4.45 to 1.67
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding218194+12.4%
In funds' top 1002−100.0%
Held by funds35.4%36.4%−1.0 pts
New / increased47 / 9359 / 78+2.2%
Reduced / sold out39 / 2326 / 28+14.8%
Put/call ratio1.674.45−62.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SLS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLS is in one of them and how their past SLS trades turned out.

SLS in the AI portfolios
Loading…

SLS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SLS in an article yet. Here's the latest on the wider market.

About SELLAS Life Sciences Group

SELLAS is a clinical stage biopharmaceutical company based in New York that develops treatments for cancer. Its lead candidate, galinpepimut-S, is an immunotherapy that targets the WT1 protein, which is found in many types of cancer, including blood cancers such as acute myeloid leukemia. The company is also developing tambiciclib, a small molecule drug that inhibits CDK9, for patients with blood and solid cancers. Both candidates are in clinical trials.

Headquarters
New York, NY
Founded
2006